AstraZeneca: Carcinoma, Non-Small-Cell Lung trials

The registry lists 209 Carcinoma, Non-Small-Cell Lung studies with AstraZeneca as lead sponsor. 25 are open to participants now and 63 have results posted.

Phase 1 46Phase 2 48Phase 3 44Phase 4 10No phase 71(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
• A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC RegionCompletedNCT06039683
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05984277Phase 3
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in CanadaCompletedNCT05933044
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2
• CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in RussiaActive, not recruitingNCT05887011
• Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEICompletedNCT05826366
• A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsActive, not recruitingNCT05801029Phase 2
• Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05687266Phase 3
• First in Human Study of AZD9592 in Solid TumorsActive, not recruitingNCT05647122Phase 1
• Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRmActive, not recruitingNCT05546866Phase 2
• A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)Active, not recruitingNCT05526755Phase 2
• A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in RussiaActive, not recruitingNCT05456867
• A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3
• A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT05221840Phase 3
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingNCT05211895Phase 3
• A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive, not recruitingNCT05120349Phase 3
• Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR MutationsActive, not recruitingNCT05103605
• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsActive, not recruitingNCT05048797Phase 3
• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive, not recruitingNCT04995523Phase 1/2
• A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerActive, not recruitingNCT04931654Phase 1/2
• A Non Interventional Pilot Study on Machine Learning for ILD Detection Based on the Patient Data From Digital Devices in Unresectable Stage III Non-Small Cell Lung Cancer Patients Receiving DurvalumabCompletedNCT04884269
• A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1
• Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:CompletedNCT04836975
• Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung CancerCompletedNCT04808050
• Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung CancerCompletedNCT04742192
• Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United KingdomCompletedNCT04667312
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT04612751Phase 1
• Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)CompletedNCT04529564
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
• Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI TherapyCompletedNCT04207775
• Stage III NSCLC RWE in Chinese PatientsCompletedNCT04023812
• Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLCCompletedNCT03995875
• Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
• Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUSCompletedNCT03918304
• Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationActive, not recruitingNCT03833154Phase 3
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive, not recruitingNCT03819465Phase 1
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
• A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung CancerActive, not recruitingNCT03800134Phase 3
• Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in BelgiumCompletedNCT03761901
• A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer PatientsCompletedNCT03725475
• Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer PatientsCompletedNCT03721289
• IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation TherapyCompletedNCT03643484
• Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).CompletedNCT03562819
• Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong KongWithdrawnNCT03519958
• Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
• Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid TumorsCompletedNCT03490669Phase 1
• A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC PatientsCompletedNCT03485326
• An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung CancerCompletedNCT03457220
• Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.CompletedNCT03219970
• Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive PatientsCompletedNCT03137264
• Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid TumoursCompletedNCT03101839Phase 1
• Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)TerminatedNCT03053297
• Asia PDL1 Study Among NSCLC PatientsCompletedNCT03037086
• Gefitinib Long-term Survivor StudyTerminatedNCT02932345
• Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLCCompletedNCT02908750Phase 1
• Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes NowTerminatedNCT02835599
• PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLCCompletedNCT02777658
• KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)CompletedNCT02777567
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedNCT02740985Phase 1
• MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedNCT02503774Phase 1
• Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)CompletedNCT02475720
• TAURAS - T790 AURA ScreenFailure SOC Registry StudyTerminatedNCT02405247
• T790M Mutation Positive 2nd Line STandard of cAre RegistryWithdrawnNCT02368990
• An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).CompletedNCT02321046
• Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedNCT02228369Phase 1
• AZD9291 in Combination With Ascending Doses of Novel TherapeuticsActive, not recruitingNCT02143466Phase 1
• MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).CompletedNCT02088112Phase 1
• A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung CancerCompletedNCT02000947Phase 1
• Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase InhibitorCompletedNCT01947868
• Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ GulfCompletedNCT01562665
• Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.CompletedNCT01525199
• To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT01185314Not applicable
• Observational Study on the Management of Patients With Non Small Cell Lung Cancer AdenocarcinomaCompletedNCT01167972
• A Non-interventional Study (NIS) Registry for the Epidemiological and Scientific Evaluation of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) (Stage IIIB/IV Non-small Cell Lung Cancer).CompletedNCT01153399
• A Retrospective Study to Investigate the Current Situation of Biopsy Testing in Swedish Inoperable Non Small Cell Lung Cancer (NSCLC) PatientsCompletedNCT01139619
• A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma HistologyCompletedNCT01106781
• Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)CompletedNCT01103089
• Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)CompletedNCT01081496
• Epidemiological Study to Describe Non Small Cell Lung Cancer (NSCLC) Clinical Management Patterns in Central Eastern Europe and Russia (Lung-EPICLIN)CompletedNCT01069835
• Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and PaclitaxelWithdrawnNCT01000896Phase 1
• A Study on the Long Term Survivals in an Expand Access Program (EAP) of IressaCompletedNCT01000740Phase 4
• Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or mCompletedNCT00997230
• Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT00956280
• Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male PatientsCompletedNCT00922025
• An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing ChemotherapyTerminatedNCT00721981
• An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckApproved for marketingNCT00684385
• Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further TreatmentApproved for marketingNCT00683306
• Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer PatientsTerminatedNCT00539331Phase 1
• Iressa as Second Line Therapy in Advanced NSCLC-AsiaCompletedNCT00478049Phase 3
• AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy RegimenCompletedNCT00372788Phase 2
• Phase II Iressa + Irradiation Followed by Chemo in NSCLCCompletedNCT00333294Phase 2
• Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00312975Phase 2
• Phase II Iressa Versus Vinorelbine (INVITE)CompletedNCT00256711Phase 2
• A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung CancerCompletedNCT00255489Phase 1
• ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung CancerCompletedNCT00252798Phase 1
• Iressa Case Control Study in JapanCompletedNCT00252759